The ANZBCTG conducts a breast cancer clinical trials research program in
Australia and New Zealand for the prevention, treatment and cure of
Women who are interested in taking part in a breast cancer clinical
trial should discuss this with their doctor. For further information
about clinical trials and how they are conducted, please click here.
Breast cancer is the most common cancer in women worldwide; rates are
highest in developing countries and the worldwide incidence is expected
to increase. Preventative treatment for women with an increased risk of
breast cancer due to a strong family history and/or other risk factors
may include treatment with drugs such as tamoxifen and anastrozole.
There are currently no ANZBCTG prevention clinical trials open for new
Breast cancer is treated both locally (surgery and/or radiotherapy) and,
when required, also systemically with drug treatments. Local treatments
are used to remove, destroy or control breast cancer cells in a
specific area, and systemic treatments are used to destroy or control
breast cancer cells which may have spread from the breast to other parts
of the body through the lymphatic system and blood vessels. Supportive
care research evaluates interventions that aim to relieve side effects
and improve quality of life for women affected by breast cancer.
Using appropriate local and systemic treatments reduces the risk of
breast cancer recurrence, improves prognosis and saves lives. Over the
last ten years there have been many improvements in local and systemic
treatments proven through breast cancer clinical trials research,
providing more patients with more treatment options tailored to their
specific type of disease. For example, sentinel node biopsy, now a
standard of care for early breast cancer, is associated with fewer side
effects and enables many patients to avoid more extensive surgery.
Treatment with aromatase inhibitors for women with hormone-sensitive
breast cancer, the addition of taxanes to chemotherapy regimens, and
trastuzumab for women with HER2-positive breast cancer, are other
examples of advances that have been achieved through clinical trials.
Many people, however, will still experience a recurrence of breast
cancer and continued research into new, more effective treatment
combinations and targeted treatments is essential. It is not always
clear why some people respond differently to treatments and have
different outcomes. Current systemic treatment clinical trials aim to
refine drug treatments in particular subgroups of women who remain at
higher risk of recurrence despite receiving the best available
treatments as standard of care. Many patients with breast cancer find
they have to make complex decisions regarding their treatment options.
Through supportive care research, tools such as decision aids may
improve patients’ ability and confidence in making informed decisions
based on their personal priorities and situation.
Please note: personal medical information or advice cannot be provided
via this website. If you have questions please contact your usual
The following ANZBCTG clinical trials are currently open: